Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, ...

Biological agents targeting interleukin-4 receptor alpha (IL-4Rα) in atopic dermatitis (AD) achieved rapid and substantial ...

A study evaluates disinfectants for decontaminating dropped implants in surgery, highlighting risks and the efficacy of CHG ...

Trial shows fewer HF hospitalizations in HFpEF ...

Angioplasty with sirolimus-coated balloons, as compared with uncoated balloons, reduced limb amputation and other adverse ...

“Eat real food.” That new message, a key pillar of the 2025-2030 Dietary Guidelines for Americans, isn’t controversial.

Clinical trials are losing participants. Patient-first design and decentralized models can help fix the dropout problem.

Stakeholders responding to recent draft guidance from the US Food and Drug Administration (FDA) on the use of minimal ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

Study findings suggest that ixekizumab provides balanced joint and skin improvements with comparable treatment persistence to other b/tsDMARDs in routine PsA care.

The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...